Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $220.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 8.7% to $220.7 million in Q4 2024 year-over-year; TTM through Sep 2025 was $220.7 million, a 67.28% decrease, with the full-year FY2024 number at $220.7 million, down 8.7% from a year prior.
  • Liabilities and Shareholders Equity was $220.7 million for Q4 2024 at Akebia Therapeutics, up from $207.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $787.7 million in Q1 2020 to a low of $207.1 million in Q3 2024.
  • A 5-year average of $461.2 million and a median of $529.3 million in 2021 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: crashed 52.12% in 2023, then fell 8.7% in 2024.
  • Akebia Therapeutics' Liabilities and Shareholders Equity stood at $644.1 million in 2020, then fell by 17.82% to $529.3 million in 2021, then tumbled by 32.74% to $356.1 million in 2022, then tumbled by 32.12% to $241.7 million in 2023, then dropped by 8.7% to $220.7 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Liabilities and Shareholders Equity are $220.7 million (Q4 2024), $207.1 million (Q3 2024), and $225.5 million (Q1 2024).